Sellas Life Sciences: A Fully Exercised Green Shoe, a Double-Digit Slide, and Two Catalysts on the Calendar
Published on 11/22/2026 at 04:20 | Editorial boerse-global.deSellas Life Sciences wrapped up its equity placement on Friday, and the stock gave back 8.1% as the new shares hit the market. The raise brought in $172.5 million gross, but the reaction says less about the money itself than about how investors are weighing fresh capital against a wider share count. That tension is the real story here — and it sits alongside a clinical program that suddenly has something to prove.
What the placement actually did
The company sold 13,269,231 shares at $13.00 apiece. The underwriting banks exercised their overallotment option in full, which is where the $172.5 million gross figure comes from; fees and expenses still have to come out of that total. The raise followed hard on the heels of positive REGAL trial results in acute myeloid leukemia, so the timing was no accident.
The dilution side of the ledger is just as concrete. Sellas posted a net loss of $10.1 million for Q3 2026, or $0.05 per share. As of September 30, 2026, cash and cash equivalents stood at $134.7 million — a snapshot of the balance sheet before the placement closed, not after.
Neither figure tells you how long the money lasts, and it would be a stretch to pretend otherwise. What the numbers do establish is a changed starting position: more cash on hand, more shares outstanding, and a longer runway to reach the milestones that matter.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
The REGAL result behind the raise
On Tuesday, Sellas reported that galinpepimut-S met the primary endpoint of overall survival in the Phase 3 REGAL study. The company put the reduction in death risk at 41% versus the best available treatment. Median overall survival came in at 24.0 months against 14.7 months for the comparator arm, a gap Sellas described as statistically significant.
In the AML Phase 3 program, the company reported a hazard ratio of 0.59 and a p-value of 0.035. Management now plans to meet with the FDA and push ahead with preparations for a biologics license application.
A clean survival win and a filed application are two different things, though, and the distinction matters for anyone trying to value the equity. The data supply the foundation for the next step; they don't substitute for it. Treating a planned FDA meeting as a completed review would be getting ahead of the evidence.
SLS009 moves onto the conference stage
The pipeline extends beyond galinpepimut-S. Sellas has flagged a presentation on SLS009 at the American Society of Hematology annual meeting, scheduled for December 12–15, 2026 in New Orleans. The company's November 12 report counted 40 patients enrolled in the Phase 2 study in newly diagnosed AML, with preliminary initial results expected in the fourth quarter of 2026.
Those data will function as fresh input for valuation, not as confirmation of a developmental win before they arrive. Still, they widen the aperture: the story is no longer only about the regulatory path for galinpepimut-S.
Sellas Life Sciences at a turning point? This analysis reveals what investors need to know now.
How to read the selloff
Friday's 8.1% decline is best understood as the market repricing the share base, not as a verdict on the science. A placement that adds both money and shares can't be reduced to a single headline — focusing only on the inflow ignores the dilution, and focusing only on the dilution ignores the inflow. Both belong in the same assessment.
My read: the raise is neither a warning signal on its own nor a seal of approval. It pairs additional financial resources with a larger share count, and the decisive variable going forward is execution — how Sellas advances its announced regulatory plans and what the next clinical readouts actually permit management to claim. That is where the next leg of the valuation should be anchored.
Ad
Sellas Life Sciences Stock: New Analysis - 22 November
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
